RxDoctor Payments Data

Fatima Wong

Critical Care Medicine · Camden, NJNPI 1730506668

Payments from drug & device makers

What this record shows

The money is spread across several categories — education (51.4%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 84.7% of it on its own, with 12 other manufacturers making up the rest. 2023 is the largest year on record at $4,873, 8.1 times the $601 reported in 2019.

$5,833in general payments, 2019–2025

Across 54 payments — averaging $108.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$5K
  • GSK$290
  • Boehringer Ingelheim$165
  • Merck$109
  • Insmed, Inc.$81
  • AstraZeneca$65
  • plus $186 from 7 others

What the payments were for

  • Travel & lodging$1,64728%
  • Food & beverage$1,18620%
  • Education$3,00051%

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,833 in reported general payments places this provider in the 85th percentile of 254 critical care medicine providers in New Jersey.

See all critical care medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$25,491
Medicare patients
112
Services billed
266

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Breztri AerosphereBudesonide/Glycopyr/Formoterol37$34,417
Spiriva RespimatTiotropium Bromide20$12,179
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$8,227
SymbicortBudesonide/Formoterol Fumarate27$7,776
Advair HfaFluticasone Propion/Salmeterol14$4,791
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate23$2,773
Albuterol Sulfate HfaAlbuterol Sulfate41$1,308
Budesonide13$498
Wixela InhubFluticasone Propion/Salmeterol12$393
Pantoprazole Sodium11$338

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBreztri Aerosphere, Symbicort$65$42,19264 claims
Boehringer IngelheimSpiriva Respimat$165$12,17920 claims
GSKTrelegy Ellipta$290$8,22713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 254 critical care medicine providers in New Jersey.

Other critical care medicine in Camden

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →